JPS585659A - 単クロ−ン性抗体を使用する免疫学的、抑制試験 - Google Patents
単クロ−ン性抗体を使用する免疫学的、抑制試験Info
- Publication number
- JPS585659A JPS585659A JP19433681A JP19433681A JPS585659A JP S585659 A JPS585659 A JP S585659A JP 19433681 A JP19433681 A JP 19433681A JP 19433681 A JP19433681 A JP 19433681A JP S585659 A JPS585659 A JP S585659A
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antigen
- substance
- sample
- bound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 title claims description 123
- 108091007433 antigens Proteins 0.000 title claims description 123
- 102000036639 antigens Human genes 0.000 title claims description 123
- 238000012360 testing method Methods 0.000 title claims description 36
- 230000005764 inhibitory process Effects 0.000 title description 14
- 230000001900 immune effect Effects 0.000 title description 5
- 239000000523 sample Substances 0.000 claims description 91
- 238000000034 method Methods 0.000 claims description 84
- 239000000126 substance Substances 0.000 claims description 76
- 230000000890 antigenic effect Effects 0.000 claims description 56
- 239000002245 particle Substances 0.000 claims description 48
- 239000012530 fluid Substances 0.000 claims description 42
- 238000006243 chemical reaction Methods 0.000 claims description 36
- 102000004190 Enzymes Human genes 0.000 claims description 27
- 108090000790 Enzymes Proteins 0.000 claims description 27
- 230000015572 biosynthetic process Effects 0.000 claims description 24
- 239000007787 solid Substances 0.000 claims description 24
- 238000003018 immunoassay Methods 0.000 claims description 15
- 229920000936 Agarose Polymers 0.000 claims description 13
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 9
- 230000037303 wrinkles Effects 0.000 claims description 9
- 239000004816 latex Substances 0.000 claims description 8
- 229920000126 latex Polymers 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 8
- -1 cells Polymers 0.000 claims description 6
- 239000013068 control sample Substances 0.000 claims description 6
- 239000000725 suspension Substances 0.000 claims description 6
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical group O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims description 5
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 claims description 4
- 239000011521 glass Substances 0.000 claims description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 4
- 238000005259 measurement Methods 0.000 claims description 4
- 229920003229 poly(methyl methacrylate) Polymers 0.000 claims description 4
- 239000004926 polymethyl methacrylate Substances 0.000 claims description 4
- 239000000377 silicon dioxide Substances 0.000 claims description 4
- 238000002798 spectrophotometry method Methods 0.000 claims description 4
- 102000011923 Thyrotropin Human genes 0.000 claims description 3
- 108010061174 Thyrotropin Proteins 0.000 claims description 3
- 238000004737 colorimetric analysis Methods 0.000 claims description 3
- 230000002285 radioactive effect Effects 0.000 claims description 3
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 claims description 3
- 238000010998 test method Methods 0.000 claims description 3
- 102000004877 Insulin Human genes 0.000 claims description 2
- 108090001061 Insulin Proteins 0.000 claims description 2
- 238000002795 fluorescence method Methods 0.000 claims description 2
- 229940125396 insulin Drugs 0.000 claims description 2
- 229920002401 polyacrylamide Polymers 0.000 claims 3
- 238000004020 luminiscence type Methods 0.000 claims 2
- 230000029264 phototaxis Effects 0.000 claims 2
- 239000000243 solution Substances 0.000 claims 2
- 102000012406 Carcinoembryonic Antigen Human genes 0.000 claims 1
- 241000255925 Diptera Species 0.000 claims 1
- 102000004641 Fetal Proteins Human genes 0.000 claims 1
- 108010003471 Fetal Proteins Proteins 0.000 claims 1
- 241000254158 Lampyridae Species 0.000 claims 1
- 210000001099 axilla Anatomy 0.000 claims 1
- 239000003086 colorant Substances 0.000 claims 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims 1
- 230000005611 electricity Effects 0.000 claims 1
- 238000006911 enzymatic reaction Methods 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 238000002649 immunization Methods 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 239000002953 phosphate buffered saline Substances 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 239000012086 standard solution Substances 0.000 claims 1
- 238000003556 assay Methods 0.000 description 65
- 238000010791 quenching Methods 0.000 description 23
- 230000000171 quenching effect Effects 0.000 description 19
- 239000000047 product Substances 0.000 description 17
- 238000011534 incubation Methods 0.000 description 15
- 229940088598 enzyme Drugs 0.000 description 12
- 238000001514 detection method Methods 0.000 description 11
- 230000002163 immunogen Effects 0.000 description 11
- 239000007790 solid phase Substances 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 239000000203 mixture Substances 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 241000894007 species Species 0.000 description 7
- 238000010521 absorption reaction Methods 0.000 description 6
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 6
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 6
- 230000035945 sensitivity Effects 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 230000003281 allosteric effect Effects 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 230000002776 aggregation Effects 0.000 description 4
- 238000004220 aggregation Methods 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 210000004408 hybridoma Anatomy 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 102000005548 Hexokinase Human genes 0.000 description 3
- 108700040460 Hexokinases Proteins 0.000 description 3
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 3
- 102000003992 Peroxidases Human genes 0.000 description 3
- 230000004520 agglutination Effects 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 238000006555 catalytic reaction Methods 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 230000009260 cross reactivity Effects 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 208000006454 hepatitis Diseases 0.000 description 3
- 231100000283 hepatitis Toxicity 0.000 description 3
- 238000010324 immunological assay Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 108040007629 peroxidase activity proteins Proteins 0.000 description 3
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 2
- 108010032595 Antibody Binding Sites Proteins 0.000 description 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 2
- 108010015776 Glucose oxidase Proteins 0.000 description 2
- 239000004366 Glucose oxidase Substances 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 230000009918 complex formation Effects 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229940116332 glucose oxidase Drugs 0.000 description 2
- 235000019420 glucose oxidase Nutrition 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- KGLZWCCDTHHPLO-UHFFFAOYSA-N 2,3-dihydropyridine-3-carboxamide Chemical compound NC(=O)C1CN=CC=C1 KGLZWCCDTHHPLO-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- NBSCHQHZLSJFNQ-GASJEMHNSA-N D-Glucose 6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 description 1
- PHOQVHQSTUBQQK-SQOUGZDYSA-N D-glucono-1,5-lactone Chemical compound OC[C@H]1OC(=O)[C@H](O)[C@@H](O)[C@@H]1O PHOQVHQSTUBQQK-SQOUGZDYSA-N 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- VFRROHXSMXFLSN-UHFFFAOYSA-N Glc6P Natural products OP(=O)(O)OCC(O)C(O)C(O)C(O)C=O VFRROHXSMXFLSN-UHFFFAOYSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 206010033546 Pallor Diseases 0.000 description 1
- 240000000220 Panda oleosa Species 0.000 description 1
- 235000016496 Panda oleosa Nutrition 0.000 description 1
- 108091000041 Phosphoenolpyruvate Carboxylase Proteins 0.000 description 1
- 102000001105 Phosphofructokinases Human genes 0.000 description 1
- 108010069341 Phosphofructokinases Proteins 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 238000003450 affinity purification method Methods 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 230000008850 allosteric inhibition Effects 0.000 description 1
- 102000013529 alpha-Fetoproteins Human genes 0.000 description 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 229910052681 coesite Inorganic materials 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 238000003271 compound fluorescence assay Methods 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 108010050222 fructose-6-phosphatase Proteins 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 235000012209 glucono delta-lactone Nutrition 0.000 description 1
- 229960003681 gluconolactone Drugs 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 210000004754 hybrid cell Anatomy 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 238000002796 luminescence method Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 238000004848 nephelometry Methods 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- KHPXUQMNIQBQEV-UHFFFAOYSA-N oxaloacetic acid Chemical compound OC(=O)CC(=O)C(O)=O KHPXUQMNIQBQEV-UHFFFAOYSA-N 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229930029653 phosphoenolpyruvate Natural products 0.000 description 1
- DTBNBXWJWCWCIK-UHFFFAOYSA-N phosphoenolpyruvic acid Chemical compound OC(=O)C(=C)OP(O)(O)=O DTBNBXWJWCWCIK-UHFFFAOYSA-N 0.000 description 1
- 208000024335 physical disease Diseases 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 239000000941 radioactive substance Substances 0.000 description 1
- 230000035943 smell Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000004879 turbidimetry Methods 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Landscapes
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US323498 | 1981-06-24 | ||
| US06/323,498 US4486530A (en) | 1980-08-04 | 1981-06-24 | Immunometric assays using monoclonal antibodies |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP12129789A Division JPH0235365A (ja) | 1981-06-24 | 1989-05-15 | 抗原性物質の存在もしくはその濃度を決定する方法 |
| JP30785091A Division JPH0572208A (ja) | 1981-06-24 | 1991-11-22 | 単クローン性抗体を使用する免疫学的、抑制試験 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS585659A true JPS585659A (ja) | 1983-01-13 |
| JPH0421819B2 JPH0421819B2 (en]) | 1992-04-14 |
Family
ID=23259453
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP19433681A Granted JPS585659A (ja) | 1981-06-24 | 1981-12-02 | 単クロ−ン性抗体を使用する免疫学的、抑制試験 |
| JP12129789A Pending JPH0235365A (ja) | 1981-06-24 | 1989-05-15 | 抗原性物質の存在もしくはその濃度を決定する方法 |
| JP30785091A Pending JPH0572208A (ja) | 1981-06-24 | 1991-11-22 | 単クローン性抗体を使用する免疫学的、抑制試験 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP12129789A Pending JPH0235365A (ja) | 1981-06-24 | 1989-05-15 | 抗原性物質の存在もしくはその濃度を決定する方法 |
| JP30785091A Pending JPH0572208A (ja) | 1981-06-24 | 1991-11-22 | 単クローン性抗体を使用する免疫学的、抑制試験 |
Country Status (1)
| Country | Link |
|---|---|
| JP (3) | JPS585659A (en]) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59219738A (ja) * | 1983-05-30 | 1984-12-11 | Ricoh Co Ltd | 複写機光学系変倍装置 |
| JPS643561A (en) * | 1987-05-29 | 1989-01-09 | Mallinckrodt Inc | Monoclonal antibody couple for insulin- like growth factor that enables immunological analysis thereof |
| JPH03118472A (ja) * | 1989-09-29 | 1991-05-21 | Sekisui Chem Co Ltd | インスリン定量方法及び定量試薬 |
| JPH03272466A (ja) * | 1989-08-25 | 1991-12-04 | Ord Corp | 多重免疫評価分析方式 |
| JPH0465473U (en]) * | 1990-10-15 | 1992-06-08 | ||
| JPH0572208A (ja) * | 1981-06-24 | 1993-03-23 | Hybritech Inc | 単クローン性抗体を使用する免疫学的、抑制試験 |
| JPH05152781A (ja) * | 1991-06-24 | 1993-06-18 | Cmk Corp | プリント配線基板の製造法 |
| JPH0650156B2 (ja) * | 1986-12-23 | 1994-06-29 | ザッツィンゲル・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング・ウント・コンパニー | 液状或いは粘性な媒体、特に潤滑物質を連続的に供給するための装置 |
| JPH06324043A (ja) * | 1993-03-23 | 1994-11-25 | Boehringer Mannheim Gmbh | 粒子状キャリヤー物質での免疫試験におけるフック作用 の低減 |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12345641B2 (en) * | 2020-04-17 | 2025-07-01 | IDEZZ Laboratories, Inc. | Fluorescence quenching immunoassay |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5144628A (en]) * | 1974-08-12 | 1976-04-16 | Syva Co | |
| JPS54136896A (en) * | 1978-04-05 | 1979-10-24 | Syva Co | Method of analyzing chemically produced fluorescence immunity |
| US4174384A (en) * | 1975-06-30 | 1979-11-13 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| JPS54151894A (en) * | 1978-04-05 | 1979-11-29 | Syva Co | Method of analyzing chemicallyyproduced immunity |
| JPS5786051A (en) * | 1980-07-28 | 1982-05-28 | Akzo Nv | Determination of antigen employing two or more monochronal antibodies |
| JPS57118159A (en) * | 1980-08-04 | 1982-07-22 | Hybritech Inc | Immunological inhibition test using signle coulomb- oriented antibody |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4120945A (en) * | 1976-07-06 | 1978-10-17 | Becton, Dickinson & Company | Substrate coated with receptor and labeled ligand for assays |
| JPS5344622A (en) * | 1976-09-30 | 1978-04-21 | Mochida Pharm Co Ltd | Immunologically measuring method |
| JPH0235944B2 (en]) * | 1980-06-20 | 1990-08-14 | Unilever Nv | |
| JPS585659A (ja) * | 1981-06-24 | 1983-01-13 | ハイブリテツク インコ−ポレ−テツド | 単クロ−ン性抗体を使用する免疫学的、抑制試験 |
-
1981
- 1981-12-02 JP JP19433681A patent/JPS585659A/ja active Granted
-
1989
- 1989-05-15 JP JP12129789A patent/JPH0235365A/ja active Pending
-
1991
- 1991-11-22 JP JP30785091A patent/JPH0572208A/ja active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5144628A (en]) * | 1974-08-12 | 1976-04-16 | Syva Co | |
| US4174384A (en) * | 1975-06-30 | 1979-11-13 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| JPS54136896A (en) * | 1978-04-05 | 1979-10-24 | Syva Co | Method of analyzing chemically produced fluorescence immunity |
| JPS54151894A (en) * | 1978-04-05 | 1979-11-29 | Syva Co | Method of analyzing chemicallyyproduced immunity |
| JPS5786051A (en) * | 1980-07-28 | 1982-05-28 | Akzo Nv | Determination of antigen employing two or more monochronal antibodies |
| JPS57118159A (en) * | 1980-08-04 | 1982-07-22 | Hybritech Inc | Immunological inhibition test using signle coulomb- oriented antibody |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0572208A (ja) * | 1981-06-24 | 1993-03-23 | Hybritech Inc | 単クローン性抗体を使用する免疫学的、抑制試験 |
| JPS59219738A (ja) * | 1983-05-30 | 1984-12-11 | Ricoh Co Ltd | 複写機光学系変倍装置 |
| JPH0650156B2 (ja) * | 1986-12-23 | 1994-06-29 | ザッツィンゲル・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング・ウント・コンパニー | 液状或いは粘性な媒体、特に潤滑物質を連続的に供給するための装置 |
| JPS643561A (en) * | 1987-05-29 | 1989-01-09 | Mallinckrodt Inc | Monoclonal antibody couple for insulin- like growth factor that enables immunological analysis thereof |
| JPH03272466A (ja) * | 1989-08-25 | 1991-12-04 | Ord Corp | 多重免疫評価分析方式 |
| JPH03118472A (ja) * | 1989-09-29 | 1991-05-21 | Sekisui Chem Co Ltd | インスリン定量方法及び定量試薬 |
| JPH0465473U (en]) * | 1990-10-15 | 1992-06-08 | ||
| JPH05152781A (ja) * | 1991-06-24 | 1993-06-18 | Cmk Corp | プリント配線基板の製造法 |
| JPH06324043A (ja) * | 1993-03-23 | 1994-11-25 | Boehringer Mannheim Gmbh | 粒子状キャリヤー物質での免疫試験におけるフック作用 の低減 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0235365A (ja) | 1990-02-05 |
| JPH0421819B2 (en]) | 1992-04-14 |
| JPH0572208A (ja) | 1993-03-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4486530A (en) | Immunometric assays using monoclonal antibodies | |
| JPH0421818B2 (en]) | ||
| Porstmann et al. | Enzyme immunoassay techniques an overview | |
| Blake et al. | Use of enzymes in immunoassay techniques. A review | |
| US5296347A (en) | Bridge immunoassay | |
| FI81680C (fi) | Homogen fluorecens immunoanalys baserad pao ett ljusabsorberande aemne. | |
| CA2137654C (en) | Method for improving measurement precision in evanescent wave optical biosensor assays | |
| JP2651060B2 (ja) | 同時較正不均質イムノアツセイ用装置 | |
| EP0270606A1 (en) | Fluorescence immunoassay involving energy transfer between two fluorophores | |
| JPS6188155A (ja) | フイコビリタンパク質による螢光エネルギ−転位 | |
| JPH0672883B2 (ja) | 分析素子 | |
| EP0149602A1 (en) | Immunometric assay using polyclonal and monoclonal antibodies and a kit for use therein | |
| EP4549943A2 (en) | A method for detecting an analyte | |
| JPS585659A (ja) | 単クロ−ン性抗体を使用する免疫学的、抑制試験 | |
| US4540660A (en) | Substrate for fluoroimmunoassay of biological fluids | |
| Wang et al. | An integrated approach to improve the assay performance of quantum dot-based lateral flow immunoassays by using silver deposition | |
| WO1993017335A1 (en) | Bridge immunoassay | |
| EP0248038A1 (en) | Idiotypic-antigenic conjunction binding assay | |
| JP4556605B2 (ja) | 標的物質の測定方法および測定試薬 | |
| CA1289874C (en) | Anti-enzyme antibody immunoassay | |
| JPH01296162A (ja) | レセプタープレインキューベーションエンザイムアッセイ | |
| JPS5890169A (ja) | 単クロ−ン性抗体を使用する免疫学的、抑制試験 | |
| Maggio et al. | Immunology: current and future technology assessment | |
| JP4286357B2 (ja) | 化学発光酵素免疫測定方法 | |
| CA1195926A (en) | Immunometric and inhibition assays using monoclonal antibodies |